FTC, Lina Khan, and the Push for Drug Patent Reform: Addressing Patent Evergreening
Tuesday, 8 October 2024, 13:04
FTC and Lina Khan's Commitment to Drug Patent Reform
The FTC, under the leadership of Lina Khan, is committed to addressing issues related to drug patent abuse and patent evergreening. Recent discussions in Congress highlight the need for substantial reform in the drug patent system to prevent unethical practices that can drive up healthcare costs.
Understanding Patent Evergreening and Its Impact
Patent evergreening refers to the practice of extending the life of patents on drugs, which can limit competition and keep prices high. PTO and FDA are being called upon to reform policies that currently enable this abuse.
Calls for Change in Regulatory Agencies
- Congress is advocating for new legislation to curb patent abuses.
- Regulatory agency reforms aim to bolster transparency and competition.
- Public health implications of patent reforms will be closely monitored.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.